1702 Patients enrolled in the accelerating medicines partnership (AMP) RA/SLE network with isolated renal disease report minimal quality of life impairment on PROMIS-29 compared to patients with extrarenal symptoms

MLA

Richard Furie, et al. “1702 Patients Enrolled in the Accelerating Medicines Partnership (AMP) RA/SLE Network with Isolated Renal Disease Report Minimal Quality of Life Impairment on PROMIS-29 Compared to Patients with Extrarenal Symptoms.” Lupus Science and Medicine, vol. 9, no. Suppl 3, Dec. 2022. EBSCOhost, https://doi.org/10.1136/lupus-2022-lupus21century.101.

APA

Richard Furie, Michelle Petri, Judith A James, Kenneth Kalunian, Maria Dall’Era, Jill Buyon, Chaim Putterman, Peter Izmirly, Betty Diamond, Jessica Li, Jennifer Anolik, H Michael Belmont, Philip Carlucci, Deepak Rao, Andrea Fava, Diane Kamen, Celine Berthier, Jose Monroy-Trujillo, Kristin Haag, … Susana Serrate-Sztein. (2022). 1702 Patients enrolled in the accelerating medicines partnership (AMP) RA/SLE network with isolated renal disease report minimal quality of life impairment on PROMIS-29 compared to patients with extrarenal symptoms. Lupus Science and Medicine, 9(Suppl 3). https://doi.org/10.1136/lupus-2022-lupus21century.101

Chicago

Richard Furie, Michelle Petri, Judith A James, Kenneth Kalunian, Maria Dall’Era, Jill Buyon, Chaim Putterman, et al. 2022. “1702 Patients Enrolled in the Accelerating Medicines Partnership (AMP) RA/SLE Network with Isolated Renal Disease Report Minimal Quality of Life Impairment on PROMIS-29 Compared to Patients with Extrarenal Symptoms.” Lupus Science and Medicine 9 (Suppl 3). doi:10.1136/lupus-2022-lupus21century.101.